(MedPage Today) — The FDA expanded the indication for tirzepatide (Mounjaro) to include reducing the risk of major adverse cardiovascular events in high-risk adults with type 2 diabetes, Eli Lilly announced.
Global type 1 diabetes prevalence…
Source link
Mounjaro's Label Expands; Type 1 Diabetes on the Rise; Testosterone and Afib
